Global X China Biotech Innovation ETF (CHB) Research
This fund commits at least 80% of its overall assets, alongside any borrowed capital used for investment, to the securities tracked by its benchmark index. This also includes American and Global Depositary Receipts that are derived from those same index securities. The underlying index itself is specifically designed to provide investors with exposure to exchange-listed companies operating directly within China's biotechnology sector. Notably, this fund operates on a non-diversified basis.
Market snapshot
- Symbol
- CHB
- Price
- $6.64
- Day change
- -0.38%
- Market cap
- $1.4M
- 52-week range
- 6.63-9.76
- Sector
- Financial Services
- Industry
- Asset Management
Peer companies
- Grizzle Growth ETF (GRZZ)
- LifeGoal Home Down Payment Investment ETF (HOM)
- KPOP and Korean Entertainment ETF (KPOP)
- Northern Lights Fund Trust IV - Long Cramer Tracker ETF (LJIM)
- NightShares 2000 ETF (NIWM)
- Simplify Next Intangible Value Index ETF (NXTV)
- Newday Sustainable Development Equity ETF (SDGS)
- Xtrackers S&P SmallCap 600 ESG ETF (SMLE)
Recent insider activity
- LYNCH GEORGE M — A-Award (7000 shares) on 2009-05-06
- MADDEN THOMAS A — A-Award (8050 shares) on 2009-05-06
- ANESTIS ROBERT W — A-Award (7000 shares) on 2009-05-06
- SCHOLTEN ROGER K — A-Award (85000 shares) on 2009-03-06
- GRIFFITHS WILLIAM C — A-Award (200000 shares) on 2009-03-06
Open Global X China Biotech Innovation ETF (CHB) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.